Brought to you by 
Clarus leads £21mm Series A in Heptares Therapeutics
13 Oct 2009
Executive Summary
GPCR drug discovery start-up Heptares Therapeutics has raised £21mm ($30mm) in its Series A financing led by Clarus Ventures, which was joined by fellow new backer Novartis Option Fund and returning shareholder MVM Life Science Partners. Each investor put £7mm into the company, and Clarus and Novartis Option Fund contributed new board members.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Clarus leads £21mm Series A in Heptares Therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice